Pietrzak K, Olszewski W
Department of Gynaecological Oncology, M. Skłodowska-Curie Memorial Cancer Center, Warszawa.
Pol J Pathol. 1998;49(3):141-4.
The aim of this work was to establish the dependence between survival and time to progression and the factor which is considered as risk factor i.e. type of DNA ploidy. The DNA ploidy was evaluated in 33 cases of ovary carcinoma selected from 314 cases. The statistically significant difference between the 5 years survivals in patients with DNA aneuploidy and patients with DNA diploidy was observed (13.6% vs 60.9%). What was also found out, was the statistically significant difference between the 5 years survivals without the progression of disease in patients with DNA aneuploidy and patients with DNA diploidy (13.6% vs 55.9%).
这项工作的目的是确定生存与疾病进展时间之间的相关性，以及被视为风险因素的因素，即DNA倍体类型。对从314例病例中选出的33例卵巢癌病例进行了DNA倍体评估。观察到DNA非整倍体患者和DNA二倍体患者的5年生存率存在统计学显著差异（13.6%对60.9%）。还发现，DNA非整倍体患者和DNA二倍体患者在疾病无进展情况下的5年生存率也存在统计学显著差异（13.6%对55.9%）。
